Go to
JCI Insight
Citations to this article
S Gupta, … , J Kim, S Gollapudi
Published April 1, 1991
Citation Information: J Clin Invest. 1991;87(4):1467-1469. https://doi.org/10.1172/JCI115154.
Citation Information: J Clin Invest. 1991;87(4):1467-1469. https://doi.org/10.1172/JCI115154.
Abstract
Itraconazole is a recently developed triazole antifungal agent that inhibits cell membrane sterol biosynthesis. Itraconazole, in a dose-dependent manner, enhanced intracellular accumulation of daunorubicin and reversed the drug resistance in murine leukemia P388/ADR cells. In addition, itraconazole corrected the altered plasma membrane potentials of P388/ADR cells. The concentrations of itraconazole that reversed drug resistance are comparable to the plasma levels achieved by therapeutic dosage used in the treatment of fungal infections. Therefore, itraconazole is a potential candidate for in vivo use to reverse multidrug resistance in cancer with added benefit of its antifungal property.
Authors
S Gupta, J Kim, S Gollapudi
Total citations by year
Citation information
Citations to this article in year 2013 (2)
| Title and authors | Publication | Year |
|---|---|---|
|
Pharmacokinetic and Pharmacodynamic Interaction of Nadolol With Itraconazole, Rifampicin and Grapefruit Juice in Healthy Volunteers: The Journal of Clinical Pharmacology
S Misaka, N Miyazaki, MS Yatabe, T Ono, Y Shikama, T Fukushima, J Kimura |
The Journal of Clinical Pharmacology | 2013 |
|
Effects of Itraconazole, Dexamethasone and Naringin on Pharmacokinetics of Nadolol in Rats
N Miyazaki, S Misaka, H Ogata, T Fukushima, J Kimura |
Drug Metabolism and Pharmacokinetics | 2013 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)